% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Stegmayr:861682,
      author       = {Stegmayr, Carina and Willuweit, Antje and Lohmann, Philipp
                      and Langen, Karl-Josef},
      title        = {{O}‑(2‑[18{F}]‑fluoroethyl)-{L}‑tyrosine ({FET}) in
                      neurooncology: {A} review of experimental results},
      journal      = {Current radiopharmaceuticals},
      volume       = {12},
      number       = {3},
      issn         = {1874-4710},
      address      = {Sharjah},
      publisher    = {Bentham Science Publ.},
      reportid     = {FZJ-2019-02119},
      pages        = {201-210},
      year         = {2019},
      abstract     = {In recent years, PET using radiolabelled amino acids has
                      gained considerable interest as an additional tool besides
                      MRI to improve the diagnosis of cerebral gliomas and brain
                      metastases. A very successful tracer in this field is
                      O-(2-[18F]fluoroethyl)-L-tyrosine (FET) which in recent
                      years has replaced short-lived tracers such as
                      [11C]-methyl-L-methionine in many neuro-oncological centers
                      in Western Europe. FET can be produced with high efficiency
                      and distributed in a satellite concept like 2-
                      [18F]fluoro-2-deoxy-D-glucose. Many clinical studies have
                      demonstrated that FET PET provides important diagnostic
                      information regarding the delineation of cerebral gliomas
                      for therapy planning, an improved differentiation of tumor
                      recurrence from treatment-related changes and sensitive
                      treatment monitoring. In parallel, a considerable number of
                      experimental studies have investigated the uptake mechanisms
                      of FET on the cellular level and the behavior of the tracer
                      in various benign lesions in order to clarify the
                      specificity of FET uptake for tumor tissue. Further studies
                      have explored the effects of treatment related tissue
                      alterations on tracer uptake such as surgery, radiation and
                      drug therapy. Finally, the role of blood-brain barrier
                      integrity for FET uptake which presents an important aspect
                      for PET tracers targeting neoplastic lesions in the brain
                      has been investigated in several studies. Based on a
                      literature research regarding experimental FET studies and
                      corresponding clinical applications this article summarizes
                      the knowledge on the uptake behavior of FET, which has been
                      collected in more than 30 experimental studies during the
                      last two decades and discusses the role of these results in
                      the clinical context.},
      cin          = {INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-4-20090406},
      pnm          = {573 - Neuroimaging (POF3-573)},
      pid          = {G:(DE-HGF)POF3-573},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:30636621},
      UT           = {WOS:000488749800003},
      doi          = {10.2174/1874471012666190111111046},
      url          = {https://juser.fz-juelich.de/record/861682},
}